HucMSC-Ex alleviates DSS-induced colitis in mice by decreasing mast cell activation via the IL-33/ST2 axis
Authors:
- 1 January 2024
- journal article
- research article
- Published by e-Century Publishing Corporation in American Journal of Translational Research
- Vol. 16 (6) , 2727-2744
Abstract
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease that poses challenges in terms of treatment. The precise mechanism underlying the role of human umbilical cord mesenchymal stem cell-derived exosome (HucMSC-Ex) in the inflammatory repair process of IBD remains elusive. Mucosal mast cells accumulate within the intestinal tract and exert regulatory functions in IBD, thus presenting a novel target for addressing this intestinal disease. Methods: A mouse model of Dextran Sulfate Sodium (DSS)-induced colitis was established and hucMSC-Ex were administered to investigate their impact on the regulation of intestinal mast cells. An in vitro co-culture model using the human clonal colorectal adenocarcinoma cell line (Caco-2) and human mast cell line (LAD2) was also established for further exploration of the effect of hucMSC-Ex. Results: We observed the accumulation of mast cells in the intestines of patients with IBD as well as mice. In colitis mice, there was an upregulation of mast cell-related tryptase, interleukin-33 (IL-33), and suppression of tumorigenicity 2 receptor (ST2 or IL1RL1), and the function of the intestinal mucosal barrier related to intestinal tight junction protein was weakened. HucMSC-Ex treatment significantly reduced mast cell infiltration and intestinal damage. In the co-culture model, a substantial number of mast cells interact with the epithelial barrier, triggering activation of the IL-33/IL1RL1 (ST2) pathway and subsequent release of inflammatory factors and trypsin. This disruption leads to aberrant expression of tight junction proteins, which can be alleviated by supplementation with hucMSC-Ex. Conclusion: Our results suggest that hucMSC-Ex may reduce the release of mast cell mediators via the IL-33/IL1RL1 (ST2) axis, thereby mitigating its detrimental effects on intestinal barrier function.Keywords
This publication has 53 references indexed in Scilit:
- Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanismGut, 2013
- Mast Cell Tryptase Reduces Junctional Adhesion Molecule-A (JAM-A) Expression in Intestinal Epithelial Cells: Implications for the Mechanisms of Barrier Dysfunction in Irritable Bowel SyndromeAmerican Journal of Gastroenterology, 2013
- Cinnamon extract inhibits degranulation and de novo synthesis of inflammatory mediators in mast cellsAllergy, 2013
- Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in miceGut, 2012
- Essential role for mast cell tryptase in acute experimental colitisProceedings of the National Academy of Sciences, 2010
- Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritisProceedings of the National Academy of Sciences, 2010
- Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanismProceedings of the National Academy of Sciences, 2009
- Intestinal 5-Hydroxytryptamine and Mast Cell Infiltration in Rat Experimental ColitisDigestive Diseases and Sciences, 2006
- Mast Cell Tryptase Controls Paracellular Permeability of the IntestineJournal of Biological Chemistry, 2005
- Key role of mast cells and their major secretory products in inflammatory bowel diseaseWorld Journal of Gastroenterology, 2004